Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

iReceptor Plus

Financiado

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T CELL RECEPTOR SEQUENCING...

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY Background: Many cutting-edge therapies rely on manipulating the adaptive immune system, which has evolved a vast diversity (repertoire) of immune receptors to recognize and remove pathogens and cancer cells. The sequence-data set... ver más

31/12/2022

BIU

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

BAR ILAN UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 21 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches

I+D

Cerrada hace 6 años

0% 100%

21 Participantes

BIU

975.75K€ | Lider

INSTITUTO DE MONOCRISTALES S...

LEITAT

280.63K€ | Participante

SORBONNE UNIVERSITE

647.00K€ | Participante

Proyectos interesantes

nextDART Next generation Detection of Antigen Responsive T cells 1M€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

PGEN Automated evaluation and correction of generation bias in im... 150K€ Cerrado

Allosteris Allosteric modulation of immune checkpoint complexes as a ne... 2M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

InteractOmics Decoding leukemia-immune cell dynamics by organism-wide cell... 1M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 48 meses Fecha Inicio: 2018-12-08
Fecha Fin: 2022-12-31

Líder del proyecto

BAR ILAN UNIVERSITY

TRL 4-5

Presupuesto del proyecto 9M€

Descripción del proyecto Background: Many cutting-edge therapies rely on manipulating the adaptive immune system, which has evolved a vast diversity (repertoire) of immune receptors to recognize and remove pathogens and cancer cells. The sequence-data sets characterizing this Adaptive Immune Receptor Repertoire (i.e., AIRR-seq data) have the potential to revolutionize vaccine research and the development of therapies against autoimmune diseases and cancer; however, AIRR-seq data are typically stored and curated by individual labs, using a variety of tools and technologies. Sharing these data in a common way across disease studies, labs, and institutions around the world will improve our ability to recognize patterns in basic research and clinical trials, and increase our confidence in these patterns. The existing iReceptor Platform uses community-developed standards to facilitate sharing of AIRR-seq data by enabling queries across a system of distributed data repositories. Project: The iReceptor Plus consortium of researchers from Europe and Canada will address several key challenges to optimally sharing AIRR-seq data among public and industrial partners: protecting patient privacy and the intellectual property of partners, performing complex analyses on data brought together from many sources, and expanding the size and number of repositories that can be integrated in the network. Impact: The iReceptor Plus project will facilitate sharing of AIRR-seq data among multiple institutions, including biopharmaceutical companies and researchers working with human confidential data, across multiple diseases, treatments and populations. This will lead to a better understanding of the causes of infectious and autoimmune diseases and cancer, which can lead to early detection and suggest novel therapies. These improvements will reduce the social and economic burden of these diseases, advance Europe and Canada’s leadership role in immunotherapy, and contribute to improved patient care worldwide

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores